torcetrapib has been researched along with thalidomide in 1 studies
Studies (torcetrapib) | Trials (torcetrapib) | Recent Studies (post-2010) (torcetrapib) | Studies (thalidomide) | Trials (thalidomide) | Recent Studies (post-2010) (thalidomide) |
---|---|---|---|---|---|
273 | 28 | 83 | 9,789 | 1,385 | 4,342 |
Protein | Taxonomy | torcetrapib (IC50) | thalidomide (IC50) |
---|---|---|---|
Cereblon isoform 4 | Magnetospirillum gryphiswaldense | 7.8 | |
Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.37 | |
Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.5 | |
DNA damage-binding protein 1 | Homo sapiens (human) | 1.38 | |
Protein cereblon | Homo sapiens (human) | 1.38 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
McCabe, C; Rasko, JE; Sipp, D | 1 |
1 other study(ies) available for torcetrapib and thalidomide
Article | Year |
---|---|
Show drugs work before selling them.
Topics: Alanine; Azepines; Child; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; History, 20th Century; History, 21st Century; Humans; Iduronate Sulfatase; Models, Economic; Mucopolysaccharidosis II; Patient Safety; Pharmaceutical Preparations; Quinolines; Reproducibility of Results; Thalidomide; United States; United States Food and Drug Administration | 2017 |